Join us for the Johns Hopkins University School of Education's William H. Hedeman Lecture featuring Jess Gartner, Group Vice President of Resource Planning Solutions at PowerSchool. The event will focus on negotiation, leadership, and entrepreneurship in the field of education technology. Date: March 7 Time: 5:30 p.m. Location: The Pava Center Register today: https://lnkd.in/eY8GpiHk
Johns Hopkins Technology Ventures (JHTV)
Research Services
Baltimore, Maryland 7,366 followers
Bringing the benefits of academic discovery to the world.
About us
Johns Hopkins Technology Ventures advances innovation ecosystems and develops tomorrow's solutions for today's biggest challenges. Our mission is to maximize the impact of Johns Hopkins University’s research excellence by facilitating the translation and commercialization of discoveries into accessible technologies, products, and services that benefit society.
- Website
-
http://ventures.jhu.edu
External link for Johns Hopkins Technology Ventures (JHTV)
- Industry
- Research Services
- Company size
- 10,001+ employees
- Headquarters
- Baltimore, Maryland
- Type
- Nonprofit
- Founded
- 2014
- Specialties
- Diagnostics, Therapeutics, Medical Devices, Research Tools, Imaging, Healthcare IT, Engineering, Robotics, Digital Innovation, Digital Health, Precision Medicine, Materials Science, Oncology, Ophthalmology, Drug Discovery, Neurology, Commercialization, and Technology Transfer
Locations
-
Primary
Get directions
1812 Ashland Avenue
Suite 110
Baltimore, Maryland 21205, US
Employees at Johns Hopkins Technology Ventures (JHTV)
Updates
-
We are proud to be part of a community that is driving innovation and making a significant impact on the world. From groundbreaking research and technological advancements to addressing some of the most pressing global challenges, The Johns Hopkins University is at the forefront of change. Join us in celebrating the incredible work being done at Johns Hopkins University and the impact it is having on the world. https://buff.ly/4hSkUNd
-
-
Last month, we proudly revealed that our startup, Protenus, specializing in healthcare compliance analytics, has been successfully acquired by Bluesight. Read their full story to gain insights into their evolution from a student-run enterprise, their contributions to Baltimore's business landscape, and the promising future of healthcare compliance and patient safety. Discover more about their journey here: https://buff.ly/41sYT1H
-
-
Research Saves Lives.
If you follow The Johns Hopkins University, you know that university research is about more than data—it’s about people. Research saves lives by bringing new treatments, cures, and hope to families everywhere. From transformative medical breakthroughs to innovations that shape tomorrow, the impact is real. Every future discovery starts with the work happening now. Share to show your support. Share so we all understand what’s at stake. Share because research saves lives.
-
Join us on March 25 for the first annual Celebration of Innovation in Medicine, co-hosted by The Johns Hopkins University School of Medicine and Johns Hopkins Technology Ventures. This event will recognize the world- and health-changing contributions of our faculty, students, and alumni innovators. RSVP today: https://buff.ly/4b4l4yB
-
-
The Pava Center's Fall 2024 Spark Cohort concluded with a showcase event with notable winners CortiSense, Parametric, StartSmart, and UrinControl, each receiving a $2,000 Judges Award. The accelerator, designed for early-stage student innovators, provided a platform for these teams to develop and pitch their ventures. Discover more about the winners: https://buff.ly/4k4UnxK
-
-
The I-Corps program is an immersive entrepreneurial training program developed by the National Science Foundation (NSF) for researchers, faculty, students, and community entrepreneurs. Participants will engage in customer discovery research to inform how to take their innovation from idea to market. The deadline to apply is March 7. Learn more: https://buff.ly/4jSVgJH
-
-
Join Anchor Ventures to hear from biotech leaders Rahul Singhvi and Dan Edelstein at the University of Maryland BioPark for "The Lab to Market Journey," an insightful discussion on biotech careers, leadership, and strategies for success, followed by a reception and networking. Register today: https://buff.ly/3X3up3N
-
-
We're proud to spotlight Personal Genome Diagnostics (PGDx) in our "10 Innovations in 10 Years" series. PGDx has transformed cancer diagnostics with groundbreaking genomic technologies. PGDx's innovations have significantly improved patient outcomes, from non-invasive blood tests to FDA-cleared solutions. Their acquisition by Labcorp in 2021 has expanded their global impact, bringing personalized cancer treatments to more patients. Learn more about their commitment to improving lives through innovation: https://buff.ly/3WZhVu8
-
-
Congratulations Pearl Diagnostics, Inc. on their $1M CARB-X award to develop a urine-based assay for the detection of P. aeruginosa.
CARB-X will award biotechnology company Pearl Diagnostics, Inc. US$1M to develop a low-cost, low turnaround time urine assay for the detection of pneumonia caused by Pseudomonas aeruginosa. Pearl Diagnostics' proprietary technology leverages their discovery that microbial extracellular vesicles (EVs) are released from organisms growing in the lungs and can be detected in the urine. This technology has already been successfully applied to detect lower respiratory infections caused by Aspergillus. The initial aim of the CARB-X-supported project is to evaluate the potential of Pearl Diagnostics' technology for developing an assay to identify Pseudomonas aeruginosa infections. Pneumonia, a lower-respiratory-tract infection (LRTI), is one of the leading causes of illness and death worldwide, particularly among vulnerable populations such as the elderly, young children, and those with compromised immune systems. Pneumonia is the leading infectious cause of death in children under five and in low-and-middle-income countries (LMICs), claiming the lives of over 700,000 children worldwide each year. In adults, LRTIs account for 2.5 million deaths annually, millions of hospitalizations, and significant healthcare costs. “Pearl Diagnostics’ innovative prototype assay has the potential to offer a groundbreaking approach to early, accurate, and non-invasive diagnosis of lower-respiratory-tract infections,” said Erin Duffy, PhD, R&D Chief of CARB-X. “The ability to detect such infections through urine, especially for patients with compromised immune systems, could significantly shift the way we diagnose and manage these multidrug-resistant infections, enabling more targeted treatments and better patient outcomes.” 🔗 Read more: bit.ly/415zdYQ #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #Diagnostics #Pneumonia #LRTI Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Bildung und Forschung Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)
-